Literature DB >> 1928767

Postoperative analgesia by intravenous clonidine.

J M Bernard1, J L Hommeril, N Passuti, M Pinaud.   

Abstract

Clonidine, an alpha 2 adrenoreceptor agonist, has nonopiate antinociceptive properties, which might be an alternative for postoperative analgesia free of opioid-induced side effects. To document the analgesic properties of intravenous clonidine during the postoperative period, 50 ASA physical status 1 patients, immediately after spinal fusion, were randomly assigned to two groups, blindly administered either clonidine (5 micrograms/kg infused the 1st h and then 0.3 microgram-1.kg-1.h-1 during 11 h) or a placebo. A visual analog scale graded from 0 (no pain) to 100 mm was used to assess pain before clonidine or placebo administration (T0), at the end of the loading dose (T1) and then every 2 h (T3, T5, T7, T9, and T11). Morphine (0.1 mg/kg) was administered intramuscularly after each pain measurement if the score was greater than 50 mm. No morphine was given at T0. Hemodynamics, blood gases and plasma clonidine concentrations were measured each time the pain score was measured. The pain score decreased from 42 +/- 5 to 26 +/- 3 mm (mean +/- standard error) in the clonidine group whereas it was unchanged in the placebo group despite a greater morphine requirement (dose for each patient: 3.8 +/- 1 vs. 10.8 +/- 1.2 mg). Clonidine delayed the onset of pain and the first request for morphine injection. Mean arterial pressure decreased to 74 +/- 2 mmHg in the clonidine group (-26 +/- 2 vs. -15 +/- 2% in the placebo group at T11) despite a significant increase in the cumulative fluid volume.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1928767     DOI: 10.1097/00000542-199110000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  23 in total

1.  [Systemic administration of alpha(2)-adrenoceptor agonists for postoperative pain reliefagonists for postoperative pain relief.].

Authors:  R Sümpelmann
Journal:  Schmerz       Date:  1995-11       Impact factor: 1.107

2.  Oral clonidine reduces postoperative PCA morphine requirements.

Authors:  J Park; J Forrest; R Kolesar; D Bhola; S Beattie; C Chu
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

3.  [Opioid-induced analgesia and hyperalgesia].

Authors:  W Koppert
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

4.  alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception.

Authors:  F Sierralta; D Naquira; G Pinardi; H F Miranda
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

Review 5.  Patient-controlled analgesia in the management of postoperative pain.

Authors:  Mona Momeni; Manuela Crucitti; Marc De Kock
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Hemodynamic effects of oral clonidine premedication in lumbar epidural anesthesia.

Authors:  Toshiaki Nishikawa; Keiichi Tajima; Tetsu Kimura; Tsuyoshi Satsumae
Journal:  J Anesth       Date:  1996-12       Impact factor: 2.078

7.  A Hypotensive Episode Predictor for Intensive Care based on Heart Rate and Blood Pressure Time Series.

Authors:  J Lee; Rg Mark
Journal:  Comput Cardiol (2010)       Date:  2011-03-22

8.  [Clonidine for remifentanil-induced hyperalgesia: a double-blind randomized, placebo-controlled study of clonidine under intra-operative use of remifentanil in elective surgery of the shoulder].

Authors:  C J Schlimp; W Pipam; C Wolrab; C Ohner; H I Kager; R Likar
Journal:  Schmerz       Date:  2011-06       Impact factor: 1.107

9.  [Effects of intravenous clonidine on recovery and postanaesthetic analgesic requirements.].

Authors:  R Sümpelmann; A Brauer; S Krohn; D Schröder; J M Strauß
Journal:  Schmerz       Date:  1994-03       Impact factor: 1.107

10.  Clonidine does not affect lidocaine seizure threshold in rats.

Authors:  M Yokoyama; M Hirakawa; H Goto
Journal:  Can J Anaesth       Date:  1993-12       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.